Login to Your Account



Bind Goes Public for Accurin Development

By Catherine Shaffer
Staff Writer

Tuesday, August 13, 2013
Bind Therapeutics Inc. plans to give the public a chance to invest in its pipeline of programmable therapeutics in an initial public offering worth $80.5 million. The cash influx will support development of its Accurins, compounds designed to target specific cells or tissues and deliver a payload to the site of disease.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription